ASX:MEM

Memphasys Stock Forecast, Price & News

Add

Compare

Today's Range N/A

50-Day Range N/A

52-Week Range N/A

Volume246,322 shs

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Receive MEM News and Ratings via Email

Sign-up to receive the latest news and ratings for Memphasys and its competitors with MarketBeat's FREE daily newsletter.

About Memphasys

Memphasys Limited, a bio-separations company, develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. It primarily develops Felix that uses high quality sperm cells from semen samples for human assisted reproductive technologies for treating male factor infertility; hydrogels; and other polymer membranes to separate cells from fluids. The company was formerly known as NuSep Holdings Limited and changed its name to Memphasys Limited in July 2016. Memphasys Limited was incorporated in 2006 and is headquartered in Homebush, Australia.

Ellume is making news and these ASX shares are surging, again
July 29, 2021 | fool.com.au

When Ellume is making news, these ASX shares are in focus
July 28, 2021 | msn.com

The Full 180: When is a Raise Market not a Raise Market?
May 30, 2021 | msn.com

ASX Small Cap Lunch Wrap: Who’s dealing with another cluster today?
May 26, 2021 | msn.com

Memphasys shares tumble 35pc after engineering flaw identified
March 7, 2021 | msn.com

California U of Pennsylvania football player Jamain Stephens Jr. dies after contracting COVID-19
September 10, 2020 | uk.finance.yahoo.com

BRIEF-Memphasys Remains On Track For First Commercial Sales Of Felix Device To Be In Q4
June 15, 2020 | www.reuters.com

Memphasys Ltd.
May 23, 2020 | www.barrons.com

Medtech needs more than a TGA tick to hit the big
April 27, 2020 | www.msn.com

Health Kick Podcast: Memphasys is electro-shocking sperm into better IVF performance
March 10, 2020 | www.msn.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange: ASX
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: ASX:MEM
Previous Symbol
CUSIP: N/A
CIK: N/A
Web: www.memphasys.com
Phone: 61 2 8415 7300
Employees: N/A
Year Founded: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: 12.20
Book Value: A$0.01 per share
Price / Book: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Net Income: N/A
Net Margins: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 62.25
Current Ratio: 4.31
Quick Ratio: 3.92

Price-To-Earnings

Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A

Miscellaneous

Outstanding Shares: N/A
Market Cap: N/A
Next Earnings Date: N/A
Optionable: Not Optionable

MarketRank^™

Overall MarketRank^™

0.96 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Memphasys.

4.8 Community Rank

Outperform Votes
Memphasys has received 15 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Memphasys has received 6 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Memphasys has received 71.43% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Memphasys and other stocks. Vote “Outperform” if you believe MEM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MEM will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Memphasys does not currently pay a dividend.
Dividend Growth
Memphasys does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Memphasys insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Memphasys (ASX:MEM) Frequently Asked Questions

What stocks does MarketBeat like better than Memphasys?: Wall Street analysts have given Memphasys a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Memphasys wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.
Who are Memphasys' key executives?: Memphasys' management team includes the following people:
Ms. Alison Mary Coutts B.E., M.B.A., B.E. (Chem), GDipBiotech, MBA, Exec. Chairman & Interim CEO
Pablo Neyertz, Director of Fin.
Nick Gorring, Operations Mang.
Mr. Malcolm Coleman, Chief Financial Officer of Nusep Ltd
Mr. Andrew Metcalfe, Company Sec.
Who are some of Memphasys' key competitors?: Some companies that are related to Memphasys include (TNGN) (TNGN), 3SBio (TRSBF), 45525 (CUR.TO) (CUR), Abattis Bioceuticals (ATTBF), Abzena (ABZA), Acrux (ACR), Actinogen Medical (ACW), AdAlta (1AD), Admedus (AHZ), Algernon Pharmaceuticals (AGNPF), Almirall (LBTSF), Amarantus BioScience (AMBS), Amplia Therapeutics (ATX), Anatara Lifesciences (ANR) and Annovis Bio (ANVS).
View all of MEM's competitors.
What is Memphasys' stock symbol?: Memphasys trades on the ASX under the ticker symbol "MEM."
How much money does Memphasys make?: Memphasys has a market capitalization of $0.00.
What is Memphasys' official website?: The official website for Memphasys is www.memphasys.com.
How can I contact Memphasys?: The company can be reached via phone at 61 2 8415 7300.

This page was last updated on 10/24/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms

Your Ultimate Investing Toolkit

Just $1.00 for your first month.